Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration;Identificación y susceptibilidad antifúngica de Candida spp aisladas de micosis invasora. Influencia del porcentaje de inhibición del crecimiento para la determinación de CIM

Revista Medica de Chile

Volumn 130, Issue 4, 2002, Pages 416-423

  Alvarado P, Daniel ^a   Díaz J, María C ^a   Silva, Víctor ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Antifungal agents; Candida; Mycoses

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; GROWTH INHIBITOR; ITRACONAZOLE; KETOCONAZOLE;

ADULT; ARTICLE; CANDIDA; CANDIDIASIS; CHILD; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; FLUCONAZOLE; GROWTH INHIBITORS; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 0346677470     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. DEMBRY LM, VÁSQUEZJA, ZERVOS MJ. DNA analysis in the study of the epidemiology of nosocomial candidiasis. Infect Control Hosp Epidemiol 1994; 15: 48-53.
2. EDMOND MB, WALLACE SE, MCLISH DK, PFALLER MA, JONES RN, WENZEL RP. Nosocomial bloodstream infections in USA hospitals: a three years analysis. Clin Infect Dis 1991; 29: 239-44.
3. HUNG CC, CHAN YC, CHANG SC, LUH KT, HSIE WC. Nosocomial Candidemia in a University Hospital in Taiwan. J Forms Med Assoc 1996; 95: 19-28.
4. PFALLER MA, WENZEL R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992; 11: 287-91.
5. BANERJEE SN, EMORI TG, CULVER DH, GAYNES RP, JARVIS WR, HORAN T ET AL, AND THE NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM, 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991; 91: 86-9.
6. COLOMBO AL. Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective. Braz J Infect Dis 2000; 3: 113-8.
7. FEBRE N, SILVA V, MEDEIROS EA, WEY SB, COLOMBO AL, FISCHMAN O. Microbiological characteristics of yeasts isolated from urinary tracts of intensive care unit patients, undergoing urinary catheterization. J Clin Microbiol 1999; 37: 1584-6.
8. PFALLER MA, JONES RN, DOERN G, SADER HS, HOLLIS RJ, MESSER SA, FOR THE SENTRY PARTICIPANT GROUP. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of Isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 1998; 36: 1886-9.
9. PFALLER MA, SONER RN, DOEN GV, FLUIT AC, VERHOEL J, SADER HS ET AL. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group. Diagn Microbiol Infect Dis 1999; 35: 19-25.
10. RODERO L, DAVEL G, CÓRDOBA S, SORIA M, CANTERO C, HOCHENFELLER F. Multicenter study on nosocomial candidiasis in the Republic of Argentina. Rev Argent Microbiol 1999; 31: 114-9.
11. ST-GERMAIN G, LAVENDIÈRE M, PELLETIER R, BOURGAULT AM, LIBMAN M, LEMIEUX C ET AL. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of 2 years (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949-53.
12. ARAJ GF, DAHER NK, TABBARAH LA. Antifungal susceptibility of Candida isolates at the American University of Beirut Medical Center. Int J Antimicrob 1998; 10: 291-6.
13. REX J, CHESTER R, COOPER JR, MERZ CR, GALGIANI WG, ANAISSIE EJ. Detection of amphotericin B resistant in Candida isolates a broth - based system. Antimicrob Agents Chemother 1995; 39: 906-9.
14. PFALLER MA, JONES RN, DOERN GV, SADER HS, MESSER SA, HOUSTON A ET AL, AND THE SENTRY PERTICIPANT GROUP. Bloodstream infections due to Candida species: SENTRY Antimocrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-51.
15. QUINDOS G, ABARCA L, CARRILLO-MUǸOZ AJ, ARÉVALO MP, BORNAY FJ, CASALS JB ET AL. Multicenter survey of "in vitro" antifungal resistance in yeats of-medical importance isolated from Spanish patient. Rev Iberoam Micol 1999; 16: 97-100.
16. WHITE TC, PFALLER MA, RINALDI MG, SMITH J, REDDIG SW. Stable of azole drug resistance asociated with a substrata of Candida albicans from an HIV-infected patient. Oral Dis 1997; 3: 5102-9.
17. CEBALLOS A, GAITAN LA, ORIHUELA F, OLEA D, CEBALLOS L, QUINDOS G. Resistencia "in vitro" a los antifúngicos en Candida albicans de pacientes infectados por el HIV y sin candidiasis oral. Rev Iberoam Micol 1999; 16: 194-7.
18. REX JH, PFALLER MA, GAǸGIANI JN, BARTLETT S, ESPINEL-INGROFF A, GHANNOUM MA ET AL. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997; 24: 235-47.
19. RINALDI MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis 1991; 13: 439-95.
20. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungical susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards. Wayne Pa 1997.
21. CUENCA-ESTRELLA M, DÍAZ-GUERRA TM, MELLADO E, RODRÍGUEZ-TUDELA JL. Influence of glucose supplementation and inoculum size of growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol 2001; 39: 525-32.
22. KURTZMAN CP, FELL JW. The yeasts: a taxonomic study. 6. Ed. Amsterdam, Elsevier. 1998; 1055 p.